Jennifer Lachey - Jul 15, 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role: Chief Scientific Officer
Signature: /s/ Keith Regnante, Attorney-in-Fact
Stock symbol: KROS
Transactions as of: Jul 15, 2022
Transactions value $: -$1,367,210
Form type: 4
Date filed: 7/19/2022, 04:40 PM
Previous filing: Jul 15, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KROS	Common Stock	Options Exercise	$13.8K	+46K	+48.41%	$0.30^*	141K	Jul 15, 2022	Direct
transaction	KROS	Common Stock	Sale	-$1.38M	-46K	-32.62%	$30.00	95.1K	Jul 15, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KROS	Employee Stock Option (right to buy)	Options Exercise	$0	-46K	-84.02%	$0.00	8.76K	Jul 15, 2022	Common Stock	46K	$0.30	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2	Immediately exercisable.